EZH2.md
... ...
@@ -2,6 +2,8 @@
2 2
bibliography: 'morinlab.bib'
3 3
csl: 'NLM.csl'
4 4
link-citations: true
5
+nocite: |
6
+ @mottokIntegrativeGenomicAnalysis2019, @morinSomaticMutationsAltering2010, @loveGeneticLandscapeMutations2012
5 7
---
6 8
[[_TOC_]]
7 9
... ...
@@ -21,14 +23,7 @@ Combination therapies including EZH2 inhibitors are also under exploration for D
21 23
22 24
## Relevance tier by entity
23 25
24
-|Entity|Tier|Description |
25
-|:------:|:----:|--------------------------------------|
26
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
27
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019]|
28
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene supported by functional data [@morinSomaticMutationsAltering2010]|
29
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene supported by functional data [@morinSomaticMutationsAltering2010]|
30
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
31
-
26
+[[include:table1_EZH2]]
32 27
33 28
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
34 29